EN DE
Watch Cannovum Cannabis AG for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cannovum Cannabis AG (27N0) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Cannovum Cannabis AG stock €0.11, price €0.48, that is 76.9% below the price, quality 49 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare DE

CC Cannovum Cannabis AG logo Thin data Nov 8, 2026

Cannovum Cannabis AG

27N0 · XETRA
Very expensive, weak quality

Our calculation puts a fair price 77% below what the stock costs today.

Quality 49/100
Fair value €0.1100 · Strongly overvalued
Weak Growth (revenue 3y −10.8 %/yr in EUR)
Trails peers (0/5)
Narrow moat 30/100 · thin data
Thin data
⚠ Thinly traded
Watch Cannovum Cannabis AG for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€26.95 €0.1790 Fair Value €0.1100 Dec 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

47‑month range €0.1790 – €26.95 · fair‑value band €0.0800 – €0.1400 · the €0.4770 price screens above the €0.1100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Cannovum Cannabis in your weekly email

Every Wednesday you see whether Cannovum Cannabis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cannovum Cannabis AG engages in the manufacturing, wholesaling, and importing of medical cannabis products in Berlin. It also focuses on the import of medical cannabis and medical-scientific education, as well as distribution for facilitated access to cannabis-based therapies.

Show moreShow less

The company was formerly known as Cannovum AG and changed its name to Cannovum Cannabis AG in April 2023. Cannovum Cannabis AG was incorporated in 2018 and is based in Berlin, Germany.

Stock analysis

Cannovum Cannabis AG (27N0) currently trades at €0.4770, while our model-based Fair Value estimate is €0.1100, 77% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 83/100, which puts the data coverage at low.

Scenario range: €0.0800 (bear) to €0.1400 (bull), the price of €0.4770 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Cannovum Cannabis AG reported revenue of €0 in FY2024 versus €5.6K in FY2020. Reported net income was −€356K in FY2025.

Key figures

Market cap €1.1M Micro · EPS (TTM) €−0.0700 · Return on equity −537% · Return on assets (EBIT) −242% (5-year average) · Operating margin −77,789% · Revenue (TTM) €4.0K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −77%, 27N0 screens richer than that median.

Fair Value models

Bear €0.0800 Fair Value €0.1100 Bull €0.1400
Price €0.4770 · Downside -76.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) €0.0800 €0.1100 €0.1400 52
All 1 models by family
Asset-Based
NCAV (Graham) €0.0800 €0.1100 €0.1400 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 16
Are margins and returns getting better?
Financial strength 96
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 35
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 23
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

27N0 screens overvalued: fair value 77% below the price. Compare with Merck KGaA →

Compare Cannovum Cannabis AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −76.9% · Bottom 25%
Profitability
Return on assets −80.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 4.11× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs 27N0
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 27N0
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 27N0
Haleon plc HLN $9.14 $8.61 −6% vs 27N0
Merck KGaA MRK €148.75 €109.18 −27% vs 27N0
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 27N0
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 27N0
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 27N0
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 27N0
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 27N0

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cannovum Cannabis AG: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cannovum Cannabis AG Fair Value". https://www.fairvalue-calculator.com/stock/27N0

Frequently asked questions

Is Cannovum Cannabis AG (27N0) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of €0.1100 versus a price of €0.4770, about 77% lower (overvalued).
What is the fair value of 27N0?
Our model-based fair value for Cannovum Cannabis AG is €0.1100 (as of Nov 8, 2026), built from audited fundamentals. The current price: €0.4770.
What is the quality score of 27N0?
Cannovum Cannabis AG has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cannovum Cannabis AG (27N0)?
Our model-based price target is the fair value of €0.1100 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario €0.0800, optimistic scenario €0.1400. It is a calculation from audited fundamentals, not an analyst target.
What is the Cannovum Cannabis AG stock forecast for 2026?
Our models put fair value at €0.1100, about 77% lower versus a price of €0.4770 (overvalued). Cautious scenario €0.0800, optimistic scenario €0.1400. The calculation is refreshed regularly with new filings.
What is the revenue of Cannovum Cannabis AG (27N0)?
Cannovum Cannabis AG reported trailing-twelve-month revenue of about €4.0K (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Cannovum Cannabis AG (27N0)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cannovum Cannabis AG it is €0.1100 per share (as of Nov 8, 2026), against a price of €0.4770. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Cannovum Cannabis AG stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 27N0 trades above its calculated fair value: price €0.4770, fair value €0.1100, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 27N0?
No. The price is what the market pays today (€0.4770); the fair value is what the company's own numbers justify (€0.1100). For Cannovum Cannabis AG the two are €0.3670 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cannovum Cannabis AG worth?
The market values Cannovum Cannabis AG at about €1.1M (market capitalisation, as of Nov 8, 2026). Per share that is €0.4770; our models calculate a fair value of €0.1100 per share.
What do the bullish and bearish scenarios say about 27N0?
Our models span a range for Cannovum Cannabis AG: cautious scenario €0.0800, base €0.1100, optimistic €0.1400 per share (as of Nov 8, 2026, price €0.4770). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 27N0 from its 52-week high?
Cannovum Cannabis AG trades at €0.4770, about 35% below its 52-week high of €0.7360 and 42% above the low of €0.3360 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €0.1100 is for.
Which stocks are comparable to Cannovum Cannabis AG?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cannovum Cannabis AG stock attractive at the current price?
The data as of Nov 8, 2026: price €0.4770, calculated fair value €0.1100 (−77%), Quality Score 49/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 27N0 calculated?
We run Cannovum Cannabis AG through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of €0.1100 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cannovum Cannabis AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cannovum Cannabis AG (27N0)?
The closing price on Nov 6, 2026 was €0.4770. Our model-based fair value is €0.1100, about 77% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cannovum Cannabis AG right now?
The price sits above even our optimistic bull case (€0.1400). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Cannovum Cannabis AG

How large is the market capitalisation of Cannovum Cannabis AG (27N0)?
The market capitalisation of Cannovum Cannabis AG is €1.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Cannovum Cannabis AG (27N0)?
Earnings per share at Cannovum Cannabis AG are €−0.0700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cannovum Cannabis AG (27N0)?
The return on equity (ROE) of Cannovum Cannabis AG is −537% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cannovum Cannabis AG (27N0)?
On an EBIT basis the return on assets of Cannovum Cannabis AG is −242% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cannovum Cannabis AG (27N0)?
The operating margin of Cannovum Cannabis AG is −77,789% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
Free · no account needed

Watch Cannovum Cannabis AG in the live analysis

One click puts Cannovum Cannabis AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.